Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
IPILIMUMAB
BRISTOL-MYERS SQUIBB CANADA
L01FX04
IPILIMUMAB
5MG
SOLUTION
IPILIMUMAB 5MG
INTRAVENOUS
10ML/40ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0153088001; AHFS:
APPROVED
2012-02-01
_Product Monograph Master Template _ _Template Date: September 2020 _ YERVOY ® (ipilimumab for injection) Page 1 of 74 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr YERVOY® Ipilimumab for injection Intravenous Infusion, 5 mg ipilimumab / mL 10 mL and 40 mL vials Antineoplastic Pr YERVOY®, indicated for: • in combination with nivolumab, for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer after prior fluoropyrimidine-based therapy in combination with oxaliplatin or irinotecan. An improvement in survival has not yet been established. has been issued market authorization WITH CONDITIONS, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for Pr YERVOY® please refer to Health Canada’s Notice of Compliance with conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice- compliance/conditions.html” Pr YERVOY®, indicated for: • the treatment of unresectable or metastatic melanoma, as a single agent. • the treatment of unresectable or metastatic melanoma in adults who have not received prior systemic therapy for unresectable or metastatic melanoma, when used in combination with nivolumab. • the treatment of adult patients with intermediate/poor-risk advanced or metastatic renal cell carcinoma (RCC), when used in combination with nivolumab. • the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), expressing _Product Monograph Master Template _ _Template Date: September 2020 _ YERVOY ® (ipilimumab for injection) Page 2 of 74 PD-L1 ≥ 1% as determined by a validated test, with no EGFR or ALK genomic tumour aberrations, and no prior systemic therapy for metastatic NSCLC, when used in combination with nivolumab. • the treatment of adult patients with metastatic NSCLC with no EGFR or ALK genomic tumour ab Baca dokumen lengkapnya